Respuesta al tratamiento con lamivudina en pacientes con hepatitis crónica por virus B
| Autor: | M. D. Mañas García, B. Piqueras Alcol, A. Hernández Albujar, P. Carpintero Briones, F. Domper Bardají |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
HBsAg
medicine.medical_specialty Population Renal function Adefovir HBeAg Gastroenterology Internal medicine Internal Medicine medicine In patient education Hepatitis education.field_of_study business.industry virus diseases Lamivudine medicine.disease digestive system diseases Lamivudina Immunology business Hepatitis crónica B medicine.drug |
| Zdroj: | Anales de Medicina Interna v.22 n.10 2005 SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname |
| Popis: | Objective: The main objective was to find a biochemistry and virology response in positive and negative HBeAg patients who had been treating with lamivudine. Furthermore, the secondary objetive was to made a description about kidney function changes that could be found in patients under treatment with lamivudine. Method: Thirty patients with chronic B hepatitis under treatment with lamivudine had been retrospectively studied since November 999 to March 2004, in a Digestive Unit, in Ciudad Real Hospital. Results: Twenty nine out of 30 patients were included, 8 out of 29 were positive HBeAg, and 21 out of 29 were negative HBeAg. Seven patients had been treater with IFN. Thus, 8 patients had been in need of adefovir treatment after lamivudine trial. The average of treatment had been 23.7 months (3 months- 46 months). In fact, none of them were clumped from positive HBsAg to negative HBsAg. Nevertheless, we have observed those results after lamivudine treatment. Firstly, 50% positive HBe Ag patients have carried on negative DNA results. Although 25% positive HBe Ag patients had conversed to negative HBe Ag. But they did not show any anti HBe. Secondly, 76% negative HBe Ag patients had been suffering a DNA decreased, even though some of them had had a negative DNA results. Thirstly, we found some lamivudine mutation (50% in possitive HBe Ag patients and 19% in negative HBe Ag patients). Finally, all the patients with negative DNA had maintained a normal AST and ALT levels. Thus, function renal had been normal under lamivudine trial. Conclusion: According to several authors, the response to lamivudine treatment had been adequate in our population. Nevertheless, our study have shown that antiHBe levels had not been suffering any change during lamivudine treatment. In addition, we have found a smaller figures (19%) of lamivudine mutations in negative HBe Ag patients than other studies (25% in patients who were followed up for 1 year). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|